Cisplatin and Etoposide with or without Veliparib in Treating Patients with Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase II, Phase IBiomarker/Laboratory analysis, Treatment18 and overE2511
NCI-2012-01985, CDR0000736704, ECOG-E2511, NCT01642251

Trial Description

Summary

This randomized phase I/II trial studies the side effects and best dose of veliparib when given together with or without cisplatin and etoposide and to see how well they work in treating patients with extensive stage small cell lung cancer or large cell neuroendocrine non-small cell lung cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cisplatin and etoposide with or without veliparib may work better in treating patients with extensive stage small cell lung cancer or metastatic large cell neuroendocrine non-small cell lung cancer.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose (RP2D) of veliparib to use in combination with cisplatin and etoposide (CE). (Phase I)

II. To determine whether the addition of ABT-888 (veliparib) to cisplatin etoposide (CE) results in improved progression free survival (PFS) over CE with placebo in the frontline therapy of newly diagnosed extensive stage small cell lung cancer. (Phase II)

SECONDARY OBJECTIVES:

I. To determine the overall survival (OS) associated with the combination of CE plus ABT-888. (Phase II)

II. To assess the overall response rate (ORR) as well as complete response rate (CRR) associated with the combination of CE plus ABT-888. (Phase II)

III. To determine the toxicity profile of the combination of ABT-888 and CE chemotherapy in this patient population. (Phase II)

IV. To conduct exploritory correlative analysis of the impact of the select biomarkers. (Phase II)

V. To compare the overall toxicity profile and specifically the incidence and severity of chemotherapy-induced peripheral neuropathy with the addition of ABT-888 to CE. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of veliparib followed by a phase II study.

Phase I: Patients receive veliparib orally (PO) twice daily (BID) on days 1-7, etoposide intravenously (IV) over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Phase II: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.

Eligibility Criteria

Inclusion Criteria:

Absolute neutrophil count >= 1,500/mm^3

Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the subject is not eligible for the study

All females of childbearing potential must have a blood test within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase[SGPT]) =< 3 times institutional ULN (=< 5 times if liver function test [LFT] elevations due to known liver metastases)

Patients must have measurable or non-measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registration (Phase I)

Patients with central nervous system (CNS) metastases or a history of CNS metastases are ineligible

Patients receiving prior radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1; no previous irradiation to the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression

Patient must be able to swallow pills

Patients must have histologically or cytologically confirmed:

Extensive stage small cell lung cancer (SCLC) or

Stage IV (M1a or M1b according to American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition) large cell neuroendocrine non-small cell lung cancer (NSCLC) or

Small cell carcinoma of unknown primary or extrapulmonary origin and must be a candidate for systemic therapy

  • NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy

PHASE II: Hemoglobin >= 9 g/dL

PHASE II: Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)

PHASE II: Creatinine =< 1.5 X ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 x ULN

PHASE II: Leukocytes >= 3,000/mm^3

Patients must NOT have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Patients cannot have had prior chemotherapy or biologic therapy for SCLC or large cell neuroendocrine NSCLC, or small cell carcinoma of unknown primary or extrapulmonary origin; patients receiving prior radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1; no previous irradiation to the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression

PHASE II: Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception

PHASE II: ECOG performance status 0 or 1

PHASE II: Absolute neutrophil count >= 1,500/mm^3

PHASE II: All females of childbearing potential must have a blood test within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) with the current month counted as month 1

PHASE II: Platelets >= 100,000/mm^3

PHASE II: Patients must NOT have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Creatinine =< 1.5 X ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 x ULN

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

PHASE II: Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the subject is not eligible for the study

Platelets >= 100,000/mm^3

PHASE II: Patients must have measurable disease based on RECIST 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registration

PHASE II: AST (SGOT) and ALT (SGPT) =< 3 times institutional ULN (=< 5 times if LFT elevations due to known liver metastases)

PHASE II: Patient must be able to swallow pills

PHASE II: Patients with CNS metastases or a history of CNS metastases are ineligible

PHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study

PHASE II: Patients may not be receiving any other investigational agents while on study

PHASE II: Patients cannot have had prior chemotherapy or biologic therapy for small cell lung cancer; patients receiving prior radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1; no previous irradiation to the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression

PHASE II: Patients must NOT have active seizure(s) or history of seizure(s)

PHASE II: Patients must have extensive stage, histologically or cytologically confirmed small cell lung cancer; NOTE: the extensive disease classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy

PHASE II: HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with veliparib; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception

Leukocytes >= 3,000/mm^3

Hemoglobin >= 9 g/dL

Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study

Patients must NOT have active seizure(s) or history of seizure(s)

Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

National Cancer Institute

  • National Cancer Institute
Taofeek Kunle Owonikoko, Principal Investigator

Trial Sites

U.S.A.

California
Loma Linda

Loma Linda University Medical Center

Hamid Reza Mirshahidi
Ph: 909-558-3375

Hamid Reza Mirshahidi
Principal Investigator

Palo Alto

Stanford Cancer Institute

Heather A. Wakelee
Ph: 650-498-7061
Email: ccto-office@stanford.edu

Heather A. Wakelee
Principal Investigator

Colorado
Aurora

Rocky Mountain Cancer Centers-Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

The Medical Center of Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Boulder

Boulder Community Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Springs

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Penrose

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Denver

Colorado Blood Cancer Institute

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Cancer Research Program CCOP

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Exempla Saint Joseph Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Porter Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Presbyterian - Saint Lukes Medical Center - Health One

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Midtown

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Rose

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rose Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Durango

Mercy Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Southwest Oncology PC

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Englewood

Comprehensive Cancer Care and Research Institute of Colorado LLC

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Swedish Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Golden

Mountain Blue Cancer Care Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greeley

North Colorado Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greenwood Village

Rocky Mountain Cancer Centers-Greenwood Village

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Lakewood

Rocky Mountain Cancer Centers-Lakewood

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Saint Anthony Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Littleton

Littleton Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Littleton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Lone Tree

Rocky Mountain Cancer Centers-Sky Ridge

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Sky Ridge Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Longmont

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Parker

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Pueblo

Rocky Mountain Cancer Centers - Pueblo

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Saint Mary Corwin Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Thornton

Rocky Mountain Cancer Centers-Thornton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Wheat Ridge

Exempla Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Hartford

Saint Francis Hospital and Medical Center

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Georgia
Decatur

Dekalb Medical Center

Jayanthi Srinivasiah
Ph: 404-501-3279

Jayanthi Srinivasiah
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Mark Alexander Taylor
Ph: 912-350-8568

Mark Alexander Taylor
Principal Investigator

Hawaii
Aiea

Oncare Hawaii Inc-Pali Momi

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Pali Momi Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Ewa Beach

The Cancer Center of Hawaii-Leeward

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Honolulu

Kapiolani Medical Center for Women and Children

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Oncare Hawaii Inc-Kuakini

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Oncare Hawaii Inc-POB II

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

OnCare Hawaii-Liliha

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Queen's Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Straub Clinic and Hospital

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

The Cancer Center of Hawaii-Liliha

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

University of Hawaii Cancer Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Lihue

Wilcox Memorial Hospital and Kauai Medical Clinic

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Post Falls

Kootenai Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Illinois
Aurora

Rush - Copley Medical Center

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Bloomington

Illinois CancerCare-Bloomington

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Saint Joseph Medical Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Canton

Illinois CancerCare-Canton

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Carbondale

Memorial Hospital of Carbondale

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Centralia

Centralia Oncology Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Chicago

John H Stroger Jr Hospital of Cook County

Thomas E. Lad
Ph: 312-864-6000

Thomas E. Lad
Principal Investigator

Northwestern University

Melissa Lynne Johnson
Ph: 312-695-1301
Email: cancer@northwestern.edu

Melissa Lynne Johnson
Principal Investigator

University of Chicago Comprehensive Cancer Center

Victoria Meucci Villaflor
Ph: 773-834-7424

Victoria Meucci Villaflor
Principal Investigator

Danville

Carle on Vermilion

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Carle Physician Group-Effingham

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Crossroads Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Eureka

Illinois CancerCare-Eureka

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Evanston

NorthShore University HealthSystem-Evanston Hospital

Thomas A. Hensing
Ph: 847-570-2109

Thomas A. Hensing
Principal Investigator

Galesburg

Illinois CancerCare Galesburg

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Illinois CancerCare-Galesburg Cottage Plaza Office

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Glenview

NorthShore University HealthSystem-Glenbrook Hospital

Thomas A. Hensing
Ph: 847-570-2109

Thomas A. Hensing
Principal Investigator

Harvey

Ingalls Memorial Hospital

Mark Farrell Kozloff
Ph: 708-915-4673
Email: clinicaltrials@ingalls.org

Mark Farrell Kozloff
Principal Investigator

Highland Park

Hematology Oncology Associates of Illinois-Highland Park

Melissa Lynne Johnson
Ph: 312-695-1301
Email: cancer@northwestern.edu

Melissa Lynne Johnson
Principal Investigator

NorthShore University HealthSystem-Highland Park Hospital

Thomas A. Hensing
Ph: 847-570-2109

Thomas A. Hensing
Principal Investigator

Joliet

Joliet Oncology-Hematology Associates Limited

Kulumani M. Sivarajan
Ph: 815-730-3098
Email: maureenc@jolietoncology.com

Kulumani M. Sivarajan
Principal Investigator

Kankakee

Presence Saint Mary's Hospital

Melissa Lynne Johnson
Ph: 312-695-1301
Email: cancer@northwestern.edu

Melissa Lynne Johnson
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Libertyville

North Shore Hematology Oncology

Melissa Lynne Johnson
Ph: 312-695-1301
Email: cancer@northwestern.edu

Melissa Lynne Johnson
Principal Investigator

Macomb

Illinois CancerCare-Macomb

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Mattoon

Carle Physician Group-Mattoon/Charleston

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Moline

Garneau, Stewart C MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Spector, David MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Trinity Medical Center

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Mount Vernon

Good Samaritan Regional Health Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

New Lennox

UC Comprehensive Cancer Center at Silver Cross

Victoria Meucci Villaflor
Ph: 773-834-7424

Victoria Meucci Villaflor
Principal Investigator

Niles

Illinois Cancer Specialists-Niles

Melissa Lynne Johnson
Ph: 312-695-1301
Email: cancer@northwestern.edu

Melissa Lynne Johnson
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Pekin

Illinois CancerCare-Pekin

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Pekin Cancer Treatment Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Peoria

Illinois CancerCare-Peoria

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Methodist Medical Center of Illinois

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

OSF Saint Francis Medical Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Peru

Illinois CancerCare-Peru

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Princeton

Illinois CancerCare-Princeton

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Rockford

SwedishAmerican Regional Cancer Center/ACT

Harvey E. Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Harvey E. Einhorn
Principal Investigator

Skokie

Hematology Oncology Associates of Illinois - Skokie

Melissa Lynne Johnson
Ph: 312-695-1301
Email: cancer@northwestern.edu

Melissa Lynne Johnson
Principal Investigator

Springfield

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Urbana

Carle Cancer Center

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

The Carle Foundation Hospital

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Yorkville

Rush-Copley Healthcare Center

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Indiana
Indianapolis

Indiana University/Melvin and Bren Simon Cancer Center

Shadia Ibrahim Jalal
Ph: 317-274-2552

Shadia Ibrahim Jalal
Principal Investigator

Michigan City

Franciscan Saint Anthony Health-Michigan City

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Woodland Cancer Care Center

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Mishawaka

Memorial Regional Cancer Center Day Road

Thomas Joseph Reid
Ph: 800-284-7370

Thomas Joseph Reid
Principal Investigator

Richmond

Reid Hospital and Health Care Services

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

South Bend

Memorial Hospital of South Bend

Thomas Joseph Reid
Ph: 800-284-7370

Thomas Joseph Reid
Principal Investigator

Northern Indiana Cancer Research Consortium CCOP

Jose A. Bufill
Ph: 574-237-1328

Jose A. Bufill
Principal Investigator

Iowa
Bettendorf

Constantinou, Costas L MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Hematology Oncology Associates-Quad Cities

Shobha R. Chitneni
Ph: 563-355-7733
Email: kedaprile@rccqc.com

Shobha R. Chitneni
Principal Investigator

Cedar Rapids

Mercy Hospital

Deborah Weil Wilbur
Ph: 319-363-2690

Deborah Weil Wilbur
Principal Investigator

Oncology Associates at Mercy Medical Center

Deborah Weil Wilbur
Ph: 319-363-2690

Deborah Weil Wilbur
Principal Investigator

Davenport

Genesis Medical Center - East Campus

George Kovach
Ph: 800-446-6088
Email: werners@genesishealth.com

George Kovach
Principal Investigator

Des Moines

Iowa Lutheran Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Oncology Research Association CCOP

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Medical Oncology and Hematology Associates-Des Moines

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Sioux City

Siouxland Regional Cancer Center

Donald B. Wender
Ph: 712-252-0088

Donald B. Wender
Principal Investigator

West Des Moines

Methodist West Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Kansas
Chanute

Cancer Center of Kansas - Chanute

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Dodge City

Cancer Center of Kansas - Dodge City

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

El Dorado

Cancer Center of Kansas - El Dorado

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Fort Scott

Cancer Center of Kansas - Fort Scott

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Independence

Cancer Center of Kansas-Independence

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kingman

Cancer Center of Kansas-Kingman

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Liberal

Cancer Center of Kansas-Liberal

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Newton

Cancer Center of Kansas - Newton

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Parsons

Cancer Center of Kansas - Parsons

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Pratt

Cancer Center of Kansas - Pratt

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Salina

Cancer Center of Kansas - Salina

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Wellington

Cancer Center of Kansas - Wellington

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Wichita

Associates In Womens Health

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Cancer Center of Kansas - Main Office

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Cancer Center of Kansas-Wichita Medical Arts Tower

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Via Christi Regional Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Winfield

Cancer Center of Kansas - Winfield

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Crestview Hills

Oncology Hematology Care Inc-Crestview

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Maine
Augusta

Harold Alfond Center for Cancer Care

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Bangor

Eastern Maine Medical Center

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Brewer

Lafayette Family Cancer Center-EMMC

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Rockport

Penobscot Bay Medical Center

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Maryland
Baltimore

Johns Hopkins University/Sidney Kimmel Cancer Center

Christine Lee Hann
Ph: 410-955-8804
Email: jhcccro@jhmi.edu

Christine Lee Hann
Principal Investigator

Sinai Hospital of Baltimore

Roberto F. Martinez
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Roberto F. Martinez
Principal Investigator

Massachusetts
Boston

Boston Medical Center

Timothy Patrick Cooley
Ph: 617-638-8265

Timothy Patrick Cooley
Principal Investigator

Springfield

Baystate Medical Center

John Charles McCann
Ph: 413-794-3565
Email: tamara.wrenn@baystatehealth.org

John Charles McCann
Principal Investigator

Worcester

University of Massachusetts Medical School

Vijay K. Kasturi
Ph: 508-856-3216
Email: cancer.research@umassmed.edu

Vijay K. Kasturi
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Escanaba

Green Bay Oncology - Escanaba

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Hurley Medical Center

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Iron Mountain

Green Bay Oncology - Iron Mountain

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Jackson

Allegiance Health

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Kalamazoo

Borgess Medical Center

Raymond Sterling Lord
Ph: 269-373-7458

Raymond Sterling Lord
Principal Investigator

Bronson Methodist Hospital

Raymond Sterling Lord
Ph: 269-373-7458

Raymond Sterling Lord
Principal Investigator

West Michigan Cancer Center

Raymond Sterling Lord
Ph: 269-373-7458

Raymond Sterling Lord
Principal Investigator

Lansing

Sparrow Hospital

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Port Huron

Saint Joseph Mercy Port Huron

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Saginaw

Saint Mary's of Michigan

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Tareq Al Baghdadi
Ph: 734-712-4673

Tareq Al Baghdadi
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Brainerd

Essentia Health Saint Joseph's Medical Center

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Burnsville

Fairview Ridges Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Coon Rapids

Mercy Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Duluth

Essentia Health Cancer Center

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Essentia Health Saint Mary's Medical Center

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Miller-Dwan Hospital

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Saint Luke's Hospital of Duluth

Basem Said Goueli
Ph: 888-823-5923
Email: ctsucontact@westat.com

Basem Said Goueli
Principal Investigator

Edina

Fairview-Southdale Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Fergus Falls

Lake Region Healthcare Corporation-Cancer Care

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Fridley

Unity Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Hutchinson

Hutchinson Area Health Care

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Saint John's Hospital - Healtheast

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Health Partners Inc

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Hennepin County Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

New Ulm

New Ulm Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Saint Paul

Regions Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

United Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Shakopee

Saint Francis Regional Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Stillwater

Lakeview Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Waconia

Ridgeview Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Willmar

Rice Memorial Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Woodbury

Minnesota Oncology and Hematology PA-Woodbury

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Missouri
Bolivar

Central Care Cancer Center-Carrie J Babb Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Bonne Terre

Parkland Health Center-Bonne Terre

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Joplin

Freeman Health System

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint John's Clinic-Rolla-Cancer and Hematology

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Louis

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Missouri Baptist Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Louis Cancer and Breast Institute-South City

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Sullivan

Missouri Baptist Sullivan Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Montana Cancer Consortium CCOP

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Saint Vincent Healthcare

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Bozeman

Bozeman Deaconess Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Butte

Saint James Community Hospital and Cancer Treatment Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Great Falls

Benefis Healthcare- Sletten Cancer Institute

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Helena

Saint Peter's Community Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Kalispell

Kalispell Regional Medical Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Missoula

Saint Patrick Hospital - Community Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Lincoln

Nebraska Cancer Research Center

Gamini S. Soori
Ph: 402-280-4100

Gamini S. Soori
Principal Investigator

Nebraska Hematology and Oncology

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Southeast Nebraska Cancer Center

Gamini S. Soori
Ph: 402-991-8070
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Norfolk

Faith Regional Medical Offices West

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

North Platte

Great Plains Regional Medical Center

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Omaha

Missouri Valley Cancer Consortium

Gamini S. Soori
Ph: 402-398-6060

Gamini S. Soori
Principal Investigator

Nebraska Methodist Hospital

Robert M. Langdon
Ph: 402-354-5144

Robert M. Langdon
Principal Investigator

Oncology Hematology West

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Oncology Hematology West PC

Gamini S. Soori
Ph: 402-991-8070
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Scottsbluff

Regional West Medical Center

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

New Hampshire
Lebanon

Dartmouth Hitchcock Medical Center

Konstantin Hristov Dragnev
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Konstantin Hristov Dragnev
Principal Investigator

Manchester

Norris Cotton Cancer Center-Manchester

Konstantin Hristov Dragnev
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Konstantin Hristov Dragnev
Principal Investigator

New Jersey
East Orange

Veterans Adminstration New Jersey Health Care System

Victor Tsu-Shih Chang
Ph: 800-475-2336
Email: patricia.goyer@med.va.gov

Victor Tsu-Shih Chang
Principal Investigator

Hamilton

The Cancer Institute of New Jersey Hamilton

Joseph Aisner
Ph: 732-235-8675

Joseph Aisner
Principal Investigator

Mount Holly

Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County

Michael S. Entmacher
Ph: 888-847-8823

Michael S. Entmacher
Principal Investigator

New Brunswick

Rutgers Cancer Institute of New Jersey

Joseph Aisner
Ph: 732-235-8675

Joseph Aisner
Principal Investigator

Voorhees

Virtua West Jersey Hospital Voorhees

Michael S. Entmacher
Ph: 888-847-8823

Michael S. Entmacher
Principal Investigator

New York
Bronx

Albert Einstein College of Medicine

Haiying Cheng
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Haiying Cheng
Principal Investigator

Montefiore Medical Center - Moses Campus

Haiying Cheng
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Haiying Cheng
Principal Investigator

Montefiore Medical Center-Einstein Campus

Haiying Cheng
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Haiying Cheng
Principal Investigator

White Plains

Dickstein Cancer Treatment Center

Dan Costin
Ph: 914-681-2290

Dan Costin
Principal Investigator

North Carolina
Asheboro

Randolph Hospital

Mohamed Kamel Mohamed
Ph: 336-832-0821

Mohamed Kamel Mohamed
Principal Investigator

Burlington

Cone Health Cancer Center at Alamance Regional

Mohamed Kamel Mohamed
Ph: 336-832-0821

Mohamed Kamel Mohamed
Principal Investigator

Clinton

Southeastern Medical Oncology Center-Clinton

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Goldsboro

Southeastern Medical Oncology Center-Goldsboro

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Wayne Memorial Hospital

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Greensboro

Cone Health Cancer Center

Mohamed Kamel Mohamed
Ph: 336-832-0821

Mohamed Kamel Mohamed
Principal Investigator

Hendersonville

Hendersonville Hematology and Oncology at Pardee

James Earl Radford
Ph: 828-696-4716

James Earl Radford
Principal Investigator

Margaret R Pardee Memorial Hospital

James Earl Radford
Ph: 828-696-4716

James Earl Radford
Principal Investigator

Jacksonville

Southeastern Medical Oncology Center-Jacksonville

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Kinston

Kinston Medical Specialists PA

Peter Robins Watson
Ph: 252-559-2200

Peter Robins Watson
Principal Investigator

Mebane

Cone Heath Cancer Center at Mebane

Mohamed Kamel Mohamed
Ph: 336-832-0821

Mohamed Kamel Mohamed
Principal Investigator

Pinehurst

FirstHealth of the Carolinas-Moore Regional Hosiptal

Charles S. Kuzma
Ph: 910-715-2200

Charles S. Kuzma
Principal Investigator

Reidsville

Annie Penn Memorial Hospital

Mohamed Kamel Mohamed
Ph: 336-832-0821

Mohamed Kamel Mohamed
Principal Investigator

Statesville

Iredell Memorial Hospital

Ruby Ann Grimm
Ph: 704-873-5661

Ruby Ann Grimm
Principal Investigator

Wilson

Southeastern Medical Oncology Center-Wilson

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Fargo

Roger Maris Cancer Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford Clinic North-Fargo

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford Medical Center-Fargo

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Grand Forks

Altru Cancer Center

Grant Richard Seeger
Ph: 701-780-6520

Grant Richard Seeger
Principal Investigator

Ohio
Akron

Summa Akron City Hospital/Cooper Cancer Center

Jennifer Eileen Payne
Ph: 330-375-6101

Jennifer Eileen Payne
Principal Investigator

Belpre

Strecker Cancer Center-Belpre

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Canton

Mercy Medical Center

Mitchell Haut
Ph: 888-293-4673

Mitchell Haut
Principal Investigator

Chillicothe

Adena Regional Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Cincinnati

Oncology Hematology Care Inc - Anderson

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc - Kenwood

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Blue Ash

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Eden Park

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Mercy West

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Columbus

Columbus Oncology and Hematology Associates Inc

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Doctors Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Grant Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Mount Carmel Health Center West

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Dayton

Good Samaritan Hospital - Dayton

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Samaritan North Health Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Delaware

Delaware Health Center-Grady Cancer Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Delaware Radiation Oncology

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Grady Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Fairfield

Oncology Hematology Care Inc-Healthplex

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Findlay

Blanchard Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Franklin

Atrium Medical Center-Middletown Regional Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Greenville

Wayne Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Kettering

Kettering Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Lancaster

Fairfield Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Marietta

Marietta Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Mount Vernon

Knox Community Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Newark

Licking Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Newark Radiation Oncology

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Springfield

Springfield Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Troy

Upper Valley Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Westerville

Saint Ann's Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Zanesville

Genesis HealthCare System

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Oklahoma
Oklahoma City

Mercy Hospital Oklahoma City

Vikki A. Canfield
Ph: 405-751-4343

Vikki A. Canfield
Principal Investigator

University of Oklahoma Health Sciences Center

Mohammad Abdul Razaq
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Mohammad Abdul Razaq
Principal Investigator

Tulsa

Tulsa Cancer Institute

Mohammad Abdul Razaq
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Mohammad Abdul Razaq
Principal Investigator

Pennsylvania
Bryn Mawr

Bryn Mawr Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Danville

Geisinger Medical Center

Rajiv Panikkar
Ph: 570-271-5251

Rajiv Panikkar
Principal Investigator

Ephrata

Ephrata Community Hospital

Amir Tabatabai
Ph: 877-441-7957

Amir Tabatabai
Principal Investigator

Gettysburg

Adams Cancer Center

Amir Tabatabai
Ph: 877-441-7957

Amir Tabatabai
Principal Investigator

Hazleton

Geisinger Medical Center-Cancer Center Hazleton

Rajiv Panikkar
Ph: 570-271-5251

Rajiv Panikkar
Principal Investigator

Hershey

Penn State Milton S Hershey Medical Center

Chandra P. Belani
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

Chandra P. Belani
Principal Investigator

Lewisburg

Geisinger Medical Oncology at Evangelical Community Hospital

Rajiv Panikkar
Ph: 570-271-5251

Rajiv Panikkar
Principal Investigator

Lewistown

Lewistown Hospital

Rajiv Panikkar
Ph: 570-271-5251

Rajiv Panikkar
Principal Investigator

Paoli

Paoli Memorial Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Philadelphia

Albert Einstein Medical Center

William J. Tester
Ph: 215-456-3880

William J. Tester
Principal Investigator

Fox Chase Cancer Center

Ranee Mehra
Ph: 215-728-4790

Ranee Mehra
Principal Investigator

Thomas Jefferson University Hospital

Barbara Grace Campling
Ph: 215-955-6084

Barbara Grace Campling
Principal Investigator

University of Pennsylvania/Abramson Cancer Center

Charu Aggarwal
Ph: 800-474-9892

Charu Aggarwal
Principal Investigator

Pottsville

Geisinger Medical Oncology-Pottsville

Rajiv Panikkar
Ph: 570-271-5251

Rajiv Panikkar
Principal Investigator

Reading

Saint Joseph Medical Center

Marc A. Rovito
Ph: 610-378-2336
Email: danielward2@catholichealth.net

Marc A. Rovito
Principal Investigator

Sayre

Guthrie Medical Group PC-Robert Packer Hospital

Bradley Walter Lash
Ph: 800-836-0388

Bradley Walter Lash
Principal Investigator

Scranton

Hematology and Oncology Associates of North East Pennsylvania

Barbara Grace Campling
Ph: 215-955-6084

Barbara Grace Campling
Principal Investigator

State College

Geisinger Medical Group

Rajiv Panikkar
Ph: 570-271-5251

Rajiv Panikkar
Principal Investigator

West Reading

Reading Hospital

Terrence Paul Cescon
Ph: 610-988-9323

Terrence Paul Cescon
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Rajiv Panikkar
Ph: 570-271-5251

Rajiv Panikkar
Principal Investigator

Wynnewood

Lankenau Medical Center

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

York

WellSpan Health-York Hospital

Amir Tabatabai
Ph: 877-441-7957

Amir Tabatabai
Principal Investigator

South Carolina
Easley

Greenville Health System Cancer Institute-Easley

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Florence

McLeod Regional Medical Center

Rajesh Bajaj
Ph: 843-679-7256

Rajesh Bajaj
Principal Investigator

Gaffney

Gibbs Cancer Center-Gaffney

Charles E. Bowers
Ph: 800-486-5941

Charles E. Bowers
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Andrews

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Butternut

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Eastside

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Faris

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Memorial Hospital

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

Charles E. Bowers
Ph: 800-486-5941

Charles E. Bowers
Principal Investigator

Greenville Health System Cancer Institute-Greer

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Spartanburg Medical Center

Charles E. Bowers
Ph: 800-486-5941

Charles E. Bowers
Principal Investigator

South Dakota
Sioux Falls

Sanford Cancer Center-Oncology Clinic

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford USD Medical Center - Sioux Falls

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Tennessee
Bristol

Wellmont Bristol Regional Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Johnson City

Wellmont Medical Associates Oncology and Hematology-Johnson City

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Kingsport

Wellmont Holston Valley Hospital and Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Wellmont Medical Associates Oncology and Hematology-Kingsport

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Nashville

Meharry Medical College

Philip Edward Lammers
Ph: 615-327-5724
Email: jmurray@mmc.edu

Philip Edward Lammers
Principal Investigator

Texas
Dallas

Parkland Memorial Hospital

David Eric Gerber
Ph: 214-648-7097

David Eric Gerber
Principal Investigator

UT Southwestern/Simmons Cancer Center-Dallas

David Eric Gerber
Ph: 214-648-7097

David Eric Gerber
Principal Investigator

Vermont
Berlin

Central Vermont Medical Center/National Life Cancer Treatment

Claire F. Verschraegen
Ph: 802-656-4101

Claire F. Verschraegen
Principal Investigator

Burlington

University of Vermont College of Medicine

Claire F. Verschraegen
Ph: 802-656-4101

Claire F. Verschraegen
Principal Investigator

Virginia
Charlottesville

University of Virginia Cancer Center

Thao P. Dang
Ph: 434-243-6143

Thao P. Dang
Principal Investigator

Martinsville

Memorial Hospital Of Martinsville

Sreedhar Katragadda
Ph: 276-666-7827

Sreedhar Katragadda
Principal Investigator

Norton

Southwest VA Regional Cancer Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

West Virginia
Morgantown

West Virginia University Healthcare

Manish Monga
Ph: 304-293-2745
Email: sfilburn@hsc.wvu.edu

Manish Monga
Principal Investigator

Wisconsin
Antigo

Langlade Hospital and Cancer Center

Hamied R. Rezazadeh
Ph: 877-405-6866

Hamied R. Rezazadeh
Principal Investigator

Green Bay

Green Bay Oncology at Saint Vincent Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Green Bay Oncology Limited at Saint Mary's Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Saint Mary's Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Saint Vincent Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Johnson Creek

UW Cancer Center Johnson Creek

Anne M. Traynor
Ph: 877-405-6866

Anne M. Traynor
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Kurt Oettel
Principal Investigator

Madison

University of Wisconsin Hospital and Clinics

Anne M. Traynor
Ph: 877-405-6866

Anne M. Traynor
Principal Investigator

Manitowoc

Holy Family Memorial Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Marinette

Bay Area Medical Center

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Mukwonago

D N Greenwald Center

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

New Richmond

Cancer Center of Western Wisconsin

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Oconto Falls

Green Bay Oncology - Oconto Falls

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Sheboygan

Saint Nicholas Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Sturgeon Bay

Green Bay Oncology - Sturgeon Bay

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Waukesha

Waukesha Memorial Hospital

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Wausau

Aspirus Regional Cancer Center

Hamied R. Rezazadeh
Ph: 877-405-6866

Hamied R. Rezazadeh
Principal Investigator

Wisconsin Rapids

Riverview Hospital

Ronnie James Kirschling
Ph: 877-405-6866

Ronnie James Kirschling
Principal Investigator

Wyoming
Cheyenne

Cheyenne Regional Medical Center-West

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Sheridan

Welch Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01642251

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.